Europe HPV Testing and Pap Test Market size was around USD 0.97 million in 2018. It is expected to grow at a CAGR of 6.1% to reach USD 1.31 billion by 2023. It captures 25% of the global market.
The Papanicolaou test is a procedure of cervical screening utilized for detecting potentially pre-cancerous and cancerous processes in the cervix (opening of the womb or uterus). Irregular findings are usually followed up by more sensitive diagnostic tests, and based on the need interventions that prevent progression to cervical cancer are implemented.
Numerous factors for example, growing aging population, rising number of cervical cancer cases, growing awareness of cervical cancer screening programs, and government initiative and funding are driving the growth of the HPV testing market. Moreover, in order to carry out awareness campaigns, the government and major companies are funding the universities for developing enhanced technologies to facilitate effective screening, to mitigate the incidence of late-stage cervical cancer.
In spite of that, changes in regulatory guidelines for cervical cancer screening and HPV vaccination are few factors hindering the growth of this market. Additionally, the uncertain reimbursement scenario is a major challenge inhibiting the growth of the HPV test and Pap test market.
HPV testing market is segmented into two major segments on the basis of test type, namely, HPV testing. Follow-up HPV testing, HPV primary testing and co-testing are three sub-categories of HPV testing. The Pap test category is estimated to command the largest share of the HPV testing market in 2018. HPV testing category is projected to grow at the highest CAGR in the forecast period because of the growing incidences of cervical cancer, rising awareness of HPV screening, along with the introduction of HPV primary test. If we go by application, the Europe HPV testing market is segmented into two major categories, namely, vaginal cancer screening and cervical cancer screening.
The cervical cancer screening application category is estimated to command the largest share of the Pap test market in 2018. This large share is because of the rising incidences of cervical cancer and government initiatives to increase the awareness regarding the benefits of cervical cancer screening. Pap test market is categorized into three segments on basis of end users, namely, laboratories, hospitals, physicians’ offices and clinics. The laboratories end-user category is likely to command the largest share of the Pap test market in 2018. Moreover, the hospitals end-user category is estimated to grow at the highest CAGR in the future, because most of the diagnostic tests are carried out in-house in hospitals using advanced technologies in relatively shorter period of time.
On the basis of geography the Europe market is segmented into UK, Spain, Germany, France and others. It is the second largest market in terms of market share. UK is the leading market in this region.
Abbott Laboratories (U.S.), Qiagen N.V. (The Netherlands), Hologic Inc. (U.S.), Roche Diagnostics (Switzerland), Quest Diagnostics (U.S.), Becton, Dickinson and Company (U.S.) are the key players operating in the HPV testing market.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 HPV Testing
5.1.3 Follow-Up HPV Testing
5.1.4 Co-Testing
5.1.5 Primary HPV Testing
5.1.6 PAP Test
5.1.7 Y-o-Y Growth Analysis, By Type
5.1.8 Market Attractiveness Analysis, By Type
5.1.9 Market Share Analysis, By Type
5.2 Application
5.2.1 Introduction
5.2.2 Cervical Cancer Screening
5.2.3 Vaginal Cancer Screening
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
5.3 End User
5.3.1 Introduction
5.3.2 Laboratories
5.3.3 Hospitals
5.3.4 Physicians’ Offices and Clinics
5.3.5 Y-o-Y Growth Analysis, By End User
5.3.6 Market Attractiveness Analysis, By End User
5.3.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Application
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Application
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Application
6.1.5.4 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Qiagen N.V.
8.3 Roche Diagnostics
8.4 Hologic, Inc.
8.5 Becton, Dickinson and Company
8.6 Quest Diagnostics
8.7 Onco Health Corporation
8.8 Seegene, Inc.
8.9 Femasys Inc.
8.10 Arbor Vita Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
